Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ioversol
Drug ID BADD_D01186
Description Ioversol is classified as an _organoiodine_ compound and is used as a contrast dye in diagnostic procedures. It contains high levels of iodine in addition to various hydrophilic groups.
Indications and Usage Optiray 350 is indicated in adults for peripheral and coronary arteriography and left ventriculography. Optiray 350 is also indicated for contrast enhanced computed tomographic imaging of the head and body, intravenous excretory urography, intravenous digital subtraction angiography and venography. Optiray 350 is indicated in children for angiocardiography. Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography. Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography.
Marketing Status approved
ATC Code V08AB07
DrugBank ID DB09134
KEGG ID D01555
MeSH ID C054871
PubChem ID 3741
TTD Drug ID D0U1ZD
NDC Product Code 0019-1323; 0019-1332; 0406-7888; 0019-1333; 57884-0015; 67684-8777
UNII N3RIB7X24K
Synonyms ioversol | Optiray 320 | Optiray | Optiray 300
Chemical Information
Molecular Formula C18H24I3N3O9
CAS Registry Number 87771-40-2
SMILES C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash papular23.03.13.0170.028454%-
Rash pruritic23.03.13.0300.059752%-
Renal colic20.02.03.010--
Renal failure20.01.03.005---
Renal infarct20.01.07.008; 24.01.11.004---
Renal tubular necrosis20.01.07.003---
Respiratory arrest22.02.01.0090.010670%-
Respiratory disorder22.02.07.0020.014227%-
Respiratory distress22.02.01.0120.028454%-
Respiratory failure14.01.04.003; 22.02.06.0020.021340%
Retching07.01.07.0020.041969%-
Retroperitoneal haemorrhage07.07.02.002; 12.01.17.018; 24.07.01.017--
Rhinorrhoea22.12.03.0210.088206%
Salivary hypersecretion07.06.01.0090.026320%-
Seizure17.12.03.0010.065443%
Shock24.06.02.0020.014227%-
Sinus arrest02.03.03.007---
Sinus bradycardia02.03.03.009--
Sinus congestion22.04.06.0010.027742%-
Skin reaction10.01.03.019; 23.03.03.0130.014227%-
Skin warm23.03.03.0140.015649%-
Sneezing22.12.03.0240.579030%
Somnolence17.02.04.006; 19.02.05.003--
Speech disorder17.02.08.003; 19.19.02.002; 22.12.03.0270.017783%-
Spinal cord injury12.01.13.002; 17.10.04.001---
Suffocation feeling22.12.02.0140.007113%-
Swelling08.01.03.0150.049082%-
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.0180.061886%-
Swollen tongue07.14.02.003; 10.01.05.015; 23.04.01.0140.070423%-
Syncope02.11.04.015; 17.02.04.008; 24.06.02.0120.049794%
The 7th Page    First    Pre   7 8 9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene